HeartBeam Inc. (NASDAQ: BEAT) has recently been granted two new U.S. patents, enhancing its portfolio in the field of remote cardiac diagnostics. These patents cover the company's compact, cable-free 3D ECG device and a rhythm analysis algorithm designed to detect arrhythmias through continuous signal input. This development is pivotal as it underscores HeartBeam's commitment to advancing cardiac care technology, enabling more accurate and accessible heart health monitoring outside traditional medical facilities.
The 3D ECG device utilizes chest and finger electrodes to capture high-fidelity signals in three dimensions, facilitating on-demand symptom recording and the synthesis of 12-lead ECGs. Currently under FDA review, the device's software is supported by data from the VALID-ECG pivotal study. Meanwhile, the rhythm algorithm enhances diagnostic precision by triggering targeted data collection during abnormal rhythm detection, applicable across various cardiac monitoring systems.
With a total of 20 issued patents and 34 additional filings, HeartBeam is positioning itself as a leader in digital cardiac care innovation. The company's future plans include integrating AI capabilities to further improve diagnostic accuracy, promising a transformative impact on how cardiac conditions are monitored and managed globally.
